NeuroScientific
BIOPHARMACEUTICALS
ASX:NSB

ASX ANNOUNCEMENT
28 SEPTEMBER 2023

DATE OF AGM & CLOSING DATE FOR DIRECTOR NOMINATIONS

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (**"NeuroScientific"** or **"the company"**) advises that, in accordance with ASX Listing Rule 3.13.1, its next Annual General Meeting (AGM) will be held at 11:00am (WST) on Thursday 23 November 2023.

In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Wednesday 4 October 2023. Any nominations must be received in writing no later than 5.00pm (WST) on 4 October 2023 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders shortly. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company's website at www.neuroscientific.com.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Steve Carter
CEO
sc@neuroscientific.com
+ 61 8 6382 1805

Abby Macnish-Niven
CFO and Company Secretary
ir@neuroscientific.com
+ 61 8 6382 1805

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.